# Immune-related adverse events of immune checkpoint inhibitors: a review

Review · Yin Q, Wu L, Han L, Zheng X, Tong R, Li L, Bai L, Bian Y

- Archive id: doi:10.3389/fimmu.2023.1167975
- Published: 2023-05-25
- Venue: Frontiers in immunology
- DOI: https://doi.org/10.3389/fimmu.2023.1167975
- PMID: 37304306
- PMCID: PMC10247998
- Citations: 367
- Source URL: https://doi.org/10.3389/fimmu.2023.1167975
- PDF: https://europepmc.org/articles/PMC10247998/pdf
- Provenance: europepmc

## Abstract

Since the first Immune Checkpoint Inhibitor was developed, tumor immunotherapy has entered a new era, and the response rate and survival rate of many cancers have also been improved. Despite the success of immune checkpoint inhibitors, resistance limits the number of patients who can achieve a lasting response, and immune-related adverse events complicate treatment. The mechanism of immune-related adverse events (irAEs) is unclear. We summarize and discuss the mechanisms of action of immune checkpoint inhibitors, the different types of immune-related adverse events and their possible mechanisms, and describe possible strategies and targets for prevention and therapeutic interventions to mitigate them.

_Abstract reproduced under CC-BY (article license as recorded by Europe PMC; abstract reproduced unmodified apart from markup removal)._

Topics: [Cancer Immunotherapy](https://space-kitty.com/topics/cancer-immunotherapy)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.